Efficacy and safety of arbidol (umifenovir) in patients with COVID-19: A systematic review and meta-analysis.

Behnam Amani Bahman Amani Sara Zareei Mahsa Zareei

Published in: Immunity, inflammation and disease (2021)

The present meta-analysis showed no significant benefit of using arbidol compared with non-antiviral treatment or other therapeutic agents against COVID-19 disease. High-quality studies are needed to establish the efficacy and safety of arbidol for COVID-19.

Keyphrases

coronavirus disease
sars cov
systematic review
case control
meta analyses
respiratory syndrome coronavirus
randomized controlled trial
combination therapy